Featured Research

from universities, journals, and other organizations

Genetic Variant Predicts Poor Response To Bypass Surgery

Date:
January 28, 2009
Source:
Critical Care
Summary:
A variant of the gene for the inflammatory modulator interleukin (IL)-18 has been found to be associated with a prolonged ICU stay after cardiopulmonary bypass surgery. Research links the TT genotype of the IL-18 9545 T/G polymorphism with a larger pro-inflammatory response.

A variant of the gene for the inflammatory modulator interleukin (IL)-18 has been found to be associated with a prolonged ICU stay after cardiopulmonary bypass (CPB) surgery. New research links the TT genotype of the IL-18 9545 T/G polymorphism with a larger pro-inflammatory response.

Professor Keith Walley worked with a team of researchers from the University of British Columbia, Canada, to investigate associations between the IL-18 haplotype and post-surgery inflammatory phenotype in 658 patients undergoing CPB. He said, "Inflammatory gene polymorphisms have been linked to the intensity of the post-operative inflammatory response and to clinical outcomes after CPB surgery. Here, we've found an IL-18 variant that is associated with increased IL-18 levels and adverse outcomes."

IL-18 is known to increase levels of the pro-inflammatory cytokine TNF-α, while reducing levels of the anti-inflammatory IL-10. The TT genotype of the IL-18 9545 T/G polymorphism is believed by the authors to cause an increase in expression of IL-18. Their research confirmed this mechanism and, according to Walley, "The resulting inflammatory response may account for the adverse clinical outcomes associated with the TT genotype post-surgery".

In the cohort studied, the TT genotype was carried by 58% of the subjects, 34% were GT and 8% were GG. Apart from a small difference in body mass index, there were no significant differences in baseline characteristics between the groups.

This research was funded by The Canadian Institutes of Health Research (CIHR).


Story Source:

The above story is based on materials provided by Critical Care. Note: Materials may be edited for content and length.


Journal Reference:

  1. David M Shaw, Ainsley M Sutherland, James A Russell, Samuel V Lichtenstein and Keith R Walley. Novel polymorphism of interleukin-18 associated with greater inflammation after cardiac surgery. Critical Care, (in press)

Cite This Page:

Critical Care. "Genetic Variant Predicts Poor Response To Bypass Surgery." ScienceDaily. ScienceDaily, 28 January 2009. <www.sciencedaily.com/releases/2009/01/090128192133.htm>.
Critical Care. (2009, January 28). Genetic Variant Predicts Poor Response To Bypass Surgery. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2009/01/090128192133.htm
Critical Care. "Genetic Variant Predicts Poor Response To Bypass Surgery." ScienceDaily. www.sciencedaily.com/releases/2009/01/090128192133.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins